BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol 2018;14:337-51. [PMID: 29578207 DOI: 10.1038/nrneph.2018.19] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. Journal of the American College of Cardiology 2020;75:1145-55. [DOI: 10.1016/j.jacc.2019.12.060] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
2 Eikelboom J, Floege J, Thadhani R, Weitz JI, Winkelmayer WC. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int 2021;100:1199-207. [PMID: 34600964 DOI: 10.1016/j.kint.2021.08.028] [Reference Citation Analysis]
3 Kalra PA, Burlacu A, Ferro CJ, Covic A. Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?: . Current Opinion in Nephrology and Hypertension 2018;27:420-5. [DOI: 10.1097/mnh.0000000000000443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Ning X, Kuang Y, Yang G, Xie J, Miao D, Guo C, Huang Z. Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial. Naunyn Schmiedebergs Arch Pharmacol 2021;394:1275-83. [PMID: 33404689 DOI: 10.1007/s00210-020-02037-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B, Lenarczyk R, Nielsen-kudsk JE, Tilz R, Kalarus Z, Boveda S, Deneke T, Heinzel FR, Landmesser U, Hildick-smith D; ESC Scientific Document Group. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update. EP Europace 2020;22:184-184. [DOI: 10.1093/europace/euz258] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
6 Mahmood M, Lip GYH. Use of Oral Anticoagulation in Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays? Response. Rev Esp Cardiol (Engl Ed) 2019;72:97-8. [PMID: 30173947 DOI: 10.1016/j.rec.2018.08.002] [Reference Citation Analysis]
7 Li Y, Lip GY. Stroke prevention in atrial fibrillation: State of the art. International Journal of Cardiology 2019;287:201-9. [DOI: 10.1016/j.ijcard.2018.09.057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Burlacu A, Genovesi S, Ortiz A, Combe C, Basile C, Schneditz D, van der Sande F, Popa GT, Morosanu C, Covic A. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant 2019;34:923-33. [PMID: 30879070 DOI: 10.1093/ndt/gfz040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
9 Verma A, Wachter R, Kowey PR, Halperin JL, Gersh BJ, Elkind MS, Kaplon RE, Ziegler PD, Sherfesee L, Reiffel JA. Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). The American Journal of Cardiology 2019;124:864-70. [DOI: 10.1016/j.amjcard.2019.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Alshogran OY. Warfarin Dosing and Outcomes in Chronic Kidney Disease: A Closer Look at Warfarin Disposition. Curr Drug Metab 2019;20:633-45. [PMID: 31267868 DOI: 10.2174/1389200220666190701095807] [Reference Citation Analysis]
11 De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F. Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study. J Am Soc Nephrol 2020;31:186-96. [PMID: 31704740 DOI: 10.1681/ASN.2019060579] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
12 Hu A, Niu J, Winkelmayer WC. Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation. Semin Nephrol 2018;38:618-28. [PMID: 30413255 DOI: 10.1016/j.semnephrol.2018.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
13 Aursulesei V, Costache II. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol 2019;42:774-82. [PMID: 31102275 DOI: 10.1002/clc.23196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
14 Giustozzi M, Franco L, Vedovati MC, Becattini C, Agnelli G. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. J Thromb Thrombolysis 2019;48:439-53. [DOI: 10.1007/s11239-019-01878-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
15 Potpara TS, Ferro C, Lip GYH, Dan GA, Lenarczyk R, Mallamaci F, Ortiz A, Sarafidis P, Ekart R, Dagres N. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. EP Europace 2020;22:496-505. [DOI: 10.1093/europace/euz358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
16 Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-lundqvist C, Boriani G, Castella M, Dan G, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau J, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, Kirchhof P, Kühne M, Aboyans V, Ahlsson A, Balsam P, Bauersachs J, Benussi S, Brandes A, Braunschweig F, Camm AJ, Capodanno D, Casadei B, Conen D, Crijns HJGM, Delgado V, Dobrev D, Drexel H, Eckardt L, Fitzsimons D, Folliguet T, Gale CP, Gorenek B, Haeusler KG, Heidbuchel H, Iung B, Katus HA, Kotecha D, Landmesser U, Leclercq C, Lewis BS, Mascherbauer J, Merino JL, Merkely B, Mont L, Mueller C, Nagy KV, Oldgren J, Pavlović N, Pedretti RFE, Petersen SE, Piccini JP, Popescu BA, Pürerfellner H, Richter DJ, Roffi M, Rubboli A, Scherr D, Schnabel RB, Simpson IA, Shlyakhto E, Sinner MF, Steffel J, Sousa-uva M, Suwalski P, Svetlosak M, Touyz RM, Dagres N, Arbelo E, Bax JJ, Blomström-lundqvist C, Boriani G, Castella M, Dan G, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau J, Lettino M, Lip GYH, Pinto FJ, Neil Thomas G, Valgimigli M, Van Gelder IC, Watkins CL, Delassi T, Sisakian HS, Scherr D, Chasnoits A, Pauw MD, Smajić E, Shalganov T, Avraamides P, Kautzner J, Gerdes C, Alaziz AA, Kampus P, Raatikainen P, Boveda S, Papiashvili G, Eckardt L, Vassilikos V, Csanádi Z, Arnar DO, Galvin J, Barsheshet A, Caldarola P, Rakisheva A, Bytyçi I, Kerimkulova A, Kalejs O, Njeim M, Puodziukynas A, Groben L, Sammut MA, Grosu A, Boskovic A, Moustaghfir A, Groot ND, Poposka L, Anfinsen O, Mitkowski PP, Cavaco DM, Siliste C, Mikhaylov EN, Bertelli L, Kojic D, Hatala R, Fras Z, Arribas F, Juhlin T, Sticherling C, Abid L, Atar I, Sychov O, Bates MGD, Zakirov NU; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 2021;42:373-498. [DOI: 10.1093/eurheartj/ehaa612] [Cited by in Crossref: 731] [Cited by in F6Publishing: 652] [Article Influence: 365.5] [Reference Citation Analysis]
17 Kotalczyk A, Ding WY, Wong CF, Rao A, Gupta D, Lip GYH. Atrial Fibrillation in Patients with Chronic Kidney Disease. Cardiol Clin 2021;39:435-46. [PMID: 34247756 DOI: 10.1016/j.ccl.2021.04.005] [Reference Citation Analysis]
18 Cases A, Gomez P, Broseta JJ, Perez Bernat E, Arjona Barrionuevo JD, Portolés JM, Gorriz JL. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Front Med (Lausanne) 2021;8:654620. [PMID: 34604247 DOI: 10.3389/fmed.2021.654620] [Reference Citation Analysis]
19 Li KHC, Jesuthasan A, Kui C, Davies R, Tse G, Lip GYH. Acute ischemic stroke management: concepts and controversies.A narrative review. Expert Rev Neurother 2021;21:65-79. [PMID: 33047640 DOI: 10.1080/14737175.2021.1836963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y. Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. Am J Kidney Dis 2021;78:678-689.e1. [PMID: 33872690 DOI: 10.1053/j.ajkd.2021.02.328] [Reference Citation Analysis]
21 Harrison SL, Lane DA, Lip GYH. Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes. Eur J Heart Fail 2020;22:136-8. [PMID: 31820530 DOI: 10.1002/ejhf.1685] [Reference Citation Analysis]
22 Parker K, Chu J, Morton M, Bhutani S, Picton M, Mitra S, Thachil J. Can direct oral anticoagulants be used in kidney transplant recipients? Clin Transplant 2021;:e14474. [PMID: 34498777 DOI: 10.1111/ctr.14474] [Reference Citation Analysis]
23 Jegatheswaran J, Hundemer GL, Massicotte-Azarniouch D, Sood MM. Anticoagulation in Patients With Advanced Chronic Kidney Disease: Walking the Fine Line Between Benefit and Harm. Can J Cardiol 2019;35:1241-55. [PMID: 31472820 DOI: 10.1016/j.cjca.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kotta PA, Elango M, Papalois V. Preoperative Cardiovascular Assessment of the Renal Transplant Recipient: A Narrative Review. J Clin Med 2021;10:2525. [PMID: 34200235 DOI: 10.3390/jcm10112525] [Reference Citation Analysis]
25 Limdi NA, Beasley TM, Sun J, Stockbridge N, Pacanowski M, Florian J. Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function. Clin Pharmacol Ther 2021;109:1593-605. [PMID: 33278832 DOI: 10.1002/cpt.2131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Gomez-Fernández P, Martín Santana A, Arjona Barrionuevo JD. Oral anticoagulation in chronic kidney disease with atrial fibrillation. Nefrologia 2021;41:137-53. [PMID: 34167767 DOI: 10.1016/j.nefroe.2021.04.005] [Reference Citation Analysis]
27 Mai L, Wu Y, Luo J, Liu X, Zhu H, Zheng H, Liang G, Zhang Y, Huang Y. A retrospective cohort study of oral anticoagulant treatment in patients with acute coronary syndrome and atrial fibrillation. BMJ Open 2019;9:e031180. [PMID: 31530618 DOI: 10.1136/bmjopen-2019-031180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Camm AJ, Atar D. Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects. Thromb Haemost 2021;121:716-30. [PMID: 33412613 DOI: 10.1055/s-0040-1721665] [Reference Citation Analysis]
29 Parker K, Thachil J. The use of direct oral anticoagulants in chronic kidney disease. Br J Haematol 2018;183:170-84. [PMID: 30183070 DOI: 10.1111/bjh.15564] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
30 Joung B, Lee JM, Lee KH, Kim TH, Choi EK, Lim WH, Kang KW, Shim J, Lim HE, Park J, Lee SR, Lee YS, Kim JB; KHRS Atrial Fibrillation Guideline Working Group. 2018 Korean Guideline of Atrial Fibrillation Management. Korean Circ J 2018;48:1033-80. [PMID: 30403013 DOI: 10.4070/kcj.2018.0339] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
31 Ferrari F, da Silveira AD, Martins VM, Franzoni LT, Zimerman LI, Stein R. Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. Cardiol Rev 2021;29:120-30. [PMID: 32332235 DOI: 10.1097/CRD.0000000000000312] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Potpara TS, Mujovic N, Lip GYH. Challenges in stroke prevention among very elderly patients with atrial fibrillation: discerning facts from prejudices. EP Europace 2020;22:173-6. [DOI: 10.1093/europace/euz344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]